This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Depression	Annexin A2 (ANXA2); helicase-like transcription factor (HLTF; SMARCA3); S100 calcium binding protein A10 (S100A10; P11)	<p>Mouse and <i>in vitro</i> studies suggest targeting SMARCA3 signaling could help treat depression. A series of <i>in vitro</i> and mouse studies identified SMARCA3 as a binding partner of the P11-ANXA2 complex, which regulates response to serotonin-specific reuptake inhibitor (SSRI) antidepressants. In <i>Smarca3</i> knockout mice, Prozac-induced neuronal and behavioral responses were lower than those seen in wild-type controls. Next steps include identifying the genes targeted by the P11-ANXA2 complex in neuronal cells and determining how those genes contribute to the effects of SSRI drugs.</p> <p>Eli Lilly and Co. markets Prozac fluoxetine to treat major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa and panic disorder.</p> <p>SciBX 6(9); doi:10.1038/scibx.2013.222 Published online March 7, 2013</p>	Patent and licensing status undisclosed	<p>Oh, Y.-S. <i>et al. Cell</i>; published online Feb. 14, 2013; doi:10.1016/j.cell.2013.01.014 Contact: Paul Greengard, The Rockefeller University, New York, N.Y. e-mail: greengard@rockefeller.edu Contact: Yong Kim, same affiliation as above e-mail: kimyo@rockefeller.edu</p>